Raptor Pharma (RPTP) Acquires IP Related to Parkinson's Disease from Université Laval

Article Stock Quotes (1) Comments (0)

Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of Parkinson's Disease from Université Laval ("Laval"), Quebec, Canada.

Raptor's agreement with Laval provides exclusive rights to technology related to the use of cysteamine and related compounds to potentially modify the progression of Parkinson's Disease. Researchers at Laval reported that administration of cystamine (an oxidized form of cysteamine) in an animal model of Parkinson's Disease showed signs of preventing neuron loss and rescuing neurons undergoing a degenerative process. Signs of restoration and partial reversal of behavioral impairments were also observed.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Viropharma, Inc. (VPHM) Said to Attract Acquisition Interest - Reuters
• MediciNova (MNOV) Pops Higher Following Presentation of Significant MN-166 Phase Ib Data
• Tesoro Logistics (TLLP) Closes $355M Northwest Products System Acquisition

Create E-mail Alert Related Categories

Corporate News, FDA, Mergers and Acquisitions

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?